Skip to main content
Premium Trial:

Request an Annual Quote

Tepnel to Offer DNA Genotek's Sample Collection Kits

NEW YORK (GenomeWeb News) – DNA Genotek said today that Tepnel Pharmaceutical Services will offer its Oragene DNA sample collection kits as part of its nucleic acid extraction and genotyping service.

Ottawa, Ontario-based DNA Genotek said that Tepnel, which is a business of Gen-Probe, will offer the Oragene kits as part of end-to-end packages that include collection, extraction, and genetic analysis.

Tepnel validated the Oragene kits for use with its nucleic acid extraction and genotyping service through its recently announced DNA Genotek Partner Program. Tepnel's service includes sample quantification and normalization, whole genome amplification, singleplex and array-based genotyping, expression analysis, and sample archiving.

"We can now offer a reliable and comprehensive end-to-end solution for DNA collection, extraction and genotyping from saliva," Gen-Probe Life Sciences Managing Director Allan Brown said in a statement. Brown also said that the system will provide a "cost-effective option for clients who are looking for complete contractual research services."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.